RUBY
Rubius Therapeutics, Inc. [RUBY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RUBY Stock Summary
In the News
RUBY Financial details
Company Rating
Neutral
Market Cap
5.16M
Income
-233.75M
Revenue
0
Book val./share
0.17
Cash/share
0.21
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
26 Feb 2024
P/E
-0.04
Forward P/E
-
PEG
-0.02
P/S
-
P/B
0.34
P/C
0.27
P/FCF
-0.07
Quick Ratio
2.39
Current Ratio
2.54
Debt / Equity
0.15
LT Debt / Equity
0.07
-
-
EPS (TTM)
-2.59
EPS next Y
-
EPS next Q
-
EPS this Y
19.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-55.34%
-
-
-
-
SMA20
100%
SMA50
100%
SMA100
-
Inst Own
3.27%
Inst Trans
0.05%
ROA
-582%
ROE
-519%
ROC
-4.08%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0032-0.3763
52W High
-
52W Low
-
RSI
87.62
Rel Volume
7.59
Avg Volume
99.54K
Volume
755.86K
Perf Week
192.31%
Perf Month
204.81%
Perf Quarter
-
Perf Half Y
233.33%
-
-
-
-
Beta
2.208
-
-
Volatility
0.02%, 0.01%
Prev Close
2.7%
Price
0.057
Change
2.7%
RUBY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -2.27 | -2.04 | -2.01 | -2.15 | -2.56 | |
| Operating cash flow per share | -1.49 | -1.4 | -1.58 | -1.65 | -1.66 | |
| Free cash flow per share | -1.87 | -1.92 | -1.65 | -1.69 | -1.72 | |
| Cash per share | 10.28 | 3.6 | 2.19 | 2.57 | 0.21 | |
| Book value per share | 10 | 3.48 | 1.76 | 2.03 | 0.17 | |
| Tangible book value per share | 10 | 3.48 | 1.76 | 2.03 | 0.17 | |
| Share holders equity per share | 10 | 3.48 | 1.76 | 2.03 | 0.17 | |
| Interest debt per share | 1.8 | 1.27 | 1.5 | 1.36 | 0.07 | |
| Market cap | 631.71M | 747.54M | 611.94M | 851.36M | 15.8M | |
| Enterprise value | 394.94M | 752.65M | 637.43M | 738.97M | 2.04M | |
| P/E ratio | -7.08 | -4.66 | -3.78 | -4.51 | -0.07 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -10.83 | -6.77 | -4.79 | -5.87 | -0.11 | |
| PFCF ratio | -8.62 | -4.95 | -4.6 | -5.72 | -0.1 | |
| P/B Ratio | 1.61 | 2.73 | 4.32 | 4.76 | 1.04 | |
| PTB ratio | 1.61 | 2.73 | 4.32 | 4.76 | 1.04 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -4.31 | -4.44 | -3.83 | -3.8 | -0.02 | |
| EV to operating cash flow | -6.77 | -6.81 | -4.99 | -5.09 | -0.01 | |
| EV to free cash flow | -5.39 | -4.98 | -4.79 | -4.97 | -0.01 | |
| Earnings yield | -0.14 | -0.21 | -0.26 | -0.22 | -14.61 | |
| Free cash flow yield | -0.12 | -0.2 | -0.22 | -0.17 | -9.84 | |
| Debt to equity | 0.18 | 0.35 | 0.82 | 0.63 | 0.15 | |
| Debt to assets | 0.15 | 0.25 | 0.42 | 0.36 | 0.1 | |
| Net debt to EBITDA | 2.58 | -0.03 | -0.15 | 0.58 | 0.12 | |
| Current ratio | 20.72 | 8.57 | 6.52 | 6.63 | 2.54 | |
| Interest coverage | -197.55 | -65.48 | -39.77 | -30.25 | -46.19 | |
| Income quality | 0.65 | 0.68 | 0.76 | 0.74 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.26 | 0.37 | 0.04 | 0.03 | 0.04 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -11.84 | -13.57 | -0.97 | -0.47 | -0.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 22.61 | 12.64 | 8.91 | 9.91 | 3.1 | |
| ROIC | -0.19 | -0.4 | -0.54 | -0.57 | -12.44 | |
| Return on tangible assets | -0.19 | -0.41 | -0.58 | -0.59 | -10.01 | |
| Graham Net | 8.09 | 2.07 | 0.5 | 0.98 | 0.12 | |
| Working capital | 394.41M | 255.51M | 153.67M | 195.16M | 12.26M | |
| Tangible asset value | 393.01M | 274.21M | 141.56M | 178.78M | 15.13M | |
| Net current asset value | 328.31M | 168.64M | 45.28M | 90.58M | 12.26M | |
| Invested capital | 0.18 | 0.35 | 0.82 | 0.63 | 0.15 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.96M | 7.53M | 6.33M | 8.53M | 6.4M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.23 | -0.59 | -1.14 | -1.06 | -15.26 | |
| Capex per share | -0.38 | -0.52 | -0.07 | -0.04 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.61 | -0.6 | -0.5 | -1.03 | -0.46 | |
| Operating cash flow per share | -0.41 | -0.52 | -0.38 | -0.4 | -0.36 | |
| Free cash flow per share | -0.43 | -0.55 | -0.4 | -0.41 | -0.36 | |
| Cash per share | 2.51 | 1.96 | 1.56 | 1.15 | 0.21 | |
| Book value per share | 1.99 | 1.49 | 1.06 | 0.4 | 0.17 | |
| Tangible book value per share | 1.99 | 1.49 | 1.06 | 0.4 | 0.17 | |
| Share holders equity per share | 1.99 | 1.49 | 1.06 | 0.4 | 0.17 | |
| Interest debt per share | 1.28 | 1.27 | 1.25 | 1.24 | 0.01 | |
| Market cap | 870.41M | 496.72M | 76.78M | 39.2M | 15.8M | |
| Enterprise value | 758.02M | 511.15M | 126.2M | 46.01M | 2.04M | |
| P/E ratio | -3.95 | -2.3 | -0.42 | -0.11 | -0.1 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -23.39 | -10.54 | -2.24 | -1.08 | -0.49 | |
| PFCF ratio | -22.56 | -10.03 | -2.13 | -1.06 | -0.48 | |
| P/B Ratio | 4.87 | 3.69 | 0.8 | 1.07 | 1.04 | |
| PTB ratio | 4.87 | 3.69 | 0.8 | 1.07 | 1.04 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -14.11 | -10.38 | -3.08 | -1.62 | 6.79 | |
| EV to operating cash flow | -20.37 | -10.84 | -3.68 | -1.27 | -0.06 | |
| EV to free cash flow | -19.65 | -10.32 | -3.5 | -1.24 | -0.06 | |
| Earnings yield | -0.06 | -0.11 | -0.59 | -2.37 | -2.61 | |
| Free cash flow yield | -0.04 | -0.1 | -0.47 | -0.95 | -2.07 | |
| Debt to equity | 0.63 | 0.84 | 1.17 | 3.03 | 0.15 | |
| Debt to assets | 0.36 | 0.42 | 0.49 | 0.65 | 0.1 | |
| Net debt to EBITDA | 2.09 | -0.29 | -1.21 | -0.24 | -45.88 | |
| Current ratio | 6.63 | 6.23 | 4.63 | 3.4 | 2.54 | |
| Interest coverage | -32.31 | -31.22 | -26.32 | -35.47 | 0.11 | |
| Income quality | 0.68 | 0.9 | 0.77 | 0.58 | 1.61 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0.05 | 0.05 | 0.02 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.4 | -1.54 | -1.1 | -0.33 | -0.62 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.23 | 4.49 | 3.47 | 3.06 | 1.31 | |
| ROIC | -0.17 | -0.18 | -0.18 | -0.5 | -0.01 | |
| Return on tangible assets | -0.17 | -0.2 | -0.2 | -0.54 | -1.79 | |
| Graham Net | 0.96 | 0.49 | 0.08 | -0.33 | 0.12 | |
| Working capital | 195.16M | 151.13M | 112.5M | 78.2M | 12.26M | |
| Tangible asset value | 178.78M | 134.65M | 95.54M | 36.59M | 15.13M | |
| Net current asset value | 90.58M | 47.57M | 9.95M | -23.29M | 12.26M | |
| Invested capital | 0.63 | 0.84 | 1.17 | 3.03 | 0.15 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 10.03M | 11.83M | 12.26M | 10.58M | 4.97M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.31 | -0.4 | -0.48 | -2.54 | -2.73 | |
| Capex per share | -0.02 | -0.03 | -0.02 | -0.01 | 0 |
RUBY Frequently Asked Questions
What is Rubius Therapeutics, Inc. stock symbol ?
Rubius Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol RUBY
What is Rubius Therapeutics, Inc. stock quote today ?
Rubius Therapeutics, Inc. stock price is $0.057 today.
Is Rubius Therapeutics, Inc. stock public?
Yes, Rubius Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 99.54K
- Market Capitalization 5.16M
- Employee 6
- CEO Dr. Laurence A. Turka M.D.
- Headquarters Cambridge,MA,US
- IPO Date 2018-07-18
-
Website
https://www.rubiustx.com 
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
